Price (delayed)
$75.17
Market cap
$3.73B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.57
Enterprise value
$3.43B
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug
There are no recent dividends present for TPTX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.